Navigation Links
Halo Therapeutics' HT-100 Receives FDA's Orphan Designation for Duchenne Muscular Dystrophy
Date:1/4/2012

NEWTON, Mass., Jan. 4, 2012 /PRNewswire/ -- Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, today announced that the United States Food and Drug Administration (FDA) granted orphan drug designation for HT-100 for treatment of Duchenne muscular dystrophy (DMD). DMD is a progressive and fatal neuromuscular disorder, which afflicts approximately 1 in 3,500 boys worldwide. HT-100, also known as halofuginone, is an orally available small molecule drug candidate that is being developed to reduce fibrosis and promote healthy muscle fiber regeneration.

The FDA grants orphan designation to promote development of therapies to treat rare diseases. Once this designation is granted, the sponsor may be eligible for a range of incentives including FDA grant funding for clinical trial costs, tax credits related to development expenses, waiver of FDA user fees, and a seven-year period of marketing exclusivity in the U.S. following FDA approval.

Halo Therapeutics has an innovative business model. The company was founded and funded to date by two DMD patient foundations, Charley's Fund (www.charleysfund.org) and the Nash Avery Foundation (www.nashaveryfoundation.org), and executive management. The company is led by biopharma veterans Marc Blaustein as CEO and Gene Williams as Executive Chairman, and has assembled a team of experienced drug developers and DMD experts to rapidly evaluate HT-100 for DMD. Mr. Blaustein brings to Halo 15 years of experience in the biopharmaceutical industry, most recently at Dyax Corp. and Alkermes. He has directed manufacturing, commercial operations, and business development functions and led development efforts for two products that subsequently received FDA approval. Mr. Williams brings decades of industry experience, including directing the fibrotic disease portf
'/>"/>

SOURCE Halo Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Echo Therapeutics Announces $3.6 Million Warrant Exercises
2. Echo Therapeutics to Present at Biotech Showcase 2012 in San Francisco
3. Orexigen® Therapeutics Completes Public Offering of Common Stock and Warrants to Purchase Common Stock
4. AuraSense Therapeutics Secures Series B Equity Investment
5. PTC Therapeutics Antibacterial Program Receives $5 Million Award from the Wellcome Trust
6. Arecor Forms Collaboration With Lilly to Develop Advanced Formulations of Protein Therapeutics
7. Cerevast Therapeutics Receives CE Mark for Clotbust ER™ Ultrasound Stroke Treatment Device
8. Orexigen® Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock
9. Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
10. Cell Therapeutics, Inc. Announces Institutional Investors Purchase $20 Million of Preferred Stock and Warrants
11. Pearl Therapeutics Reports Positive Phase 2b Results of PT001 in Patients With COPD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... the unsolicited Proposal (the "Proposal") from Mylan NV ("Mylan") ... acquire all of the outstanding shares of Perrigo for ... its financial and legal advisors, the Board unanimously concluded ... future growth prospects and is not in the best ...
(Date:4/21/2015)... April 21, 2015 EpiCast Report: Sepsis - ... is a life-threatening complication arising from an infection; it ... its own tissues and organs. Anyone can develop sepsis; ... <1 year of age, older adults, and those ... for the year 2013 showed that there are around ...
(Date:4/21/2015)... 21. April 2015  CorTechs Labs, der ... Analyse des Hirnvolumens freut sich, eine Partnerschaft ... bekannt geben zu können. Die Unternehmen werden ... Hirnvolumens zusammenarbeiten, der die Identifizierung, Messung und ... mit multipler Sklerose als Ziel hat. ...
Breaking Medicine Technology:Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 2Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 3Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 4Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 5Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 6Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 7Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 8Perrigo Board Unanimously Rejects Unsolicited Proposal From Mylan 9EpiCast Report: Sepsis - Epidemiology Forecast to 2023 2EpiCast Report: Sepsis - Epidemiology Forecast to 2023 3CorTechs Labs kündigt Partnerschaft für die Bereitstellung umfassender Lösungen zur Quantifizierung des Verlustes von Hirnvolumen bei multipler Sklerose an 2
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced ... Lynch Health Care Conference on Thursday, May 12, 2011 at ... Interested parties may access a live webcast of the ... It is recommended that listeners log on ...
... American Regent announced today that it had resumed the ...  Release of products is being prioritized and American Regent is ... that supplies of critically needed medications are available for patient ... are available from your local Wholesaler or Distributor. ...
Cached Medicine Technology:Onyx Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2American Regent Resumes Shipment of Injectable Products 2
(Date:4/21/2015)... Angelo’s FabriClean has recently announced that ... clients that avail the area rug cleaning services. Area ... with hi-tech equipments, making use of the quick drying ... natural, high pressure steam extraction to clean even the ... area rugs made with delicate fabric. , “Good ...
(Date:4/21/2015)... April 21, 2015 Catalent (Booth ... technologies and development solutions for drugs, biologics and ... ADVASEPT™ Lock, a stopper-less, glass- and needle-free vial ... medications. Easily opened, ADVASEPT Lock attaches to a ... container closure with the security of an advanced ...
(Date:4/21/2015)... QuickMedical, a veteran-owned leader in ... represents Schiller America's line of Ambulatory ... and Vital Signs Monitors, among many other items. ... global leader in the development and production of ... close cooperation with the world's leading physicians and ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 The ... Citrate Industry is a professional and in-depth study ... Sodium Citrate Market with a focus on ... in the sodium citrate market research are Cargill, ... Natural Biological, Cofco Biochemical, Capchem, Lianyungang Mupro Fi, ...
(Date:4/21/2015)... April 21, 2015 Further strengthening ties ... $1.2 million in donated goods and services to the ... through the USF Health BRIDGE Healthcare Clinic. , The ... clinic in its eighth year – provides primary medical ... one night a week inside the USF Health Morsani ...
Breaking Medicine News(10 mins):Health News:Angelo’s FabriClean Now Offers Area Rug Cleaning in South Surrey with Complimentary Pick-Up and Delivery 2Health News:Catalent Announces the Expansion of its Advanced, Aseptic, Glass-Free Injectable Platform with New ADVASEPT™ Lock Delivery Technology 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 2Health News:Sodium Citrate Industry Global Key Manufacturers Analysis Report 2015-2020 3Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 2Health News:USF Health and Florida Hospital Tampa Partner to Expand BRIDGE Clinic 3
... 24, 2011David Satcher, MD, PhD, former U.S. Surgeon General, describes ... and adult health that we are facing today," calling for ... in the June issue of Childhood Obesity , a ... is available online. A long-time advocate in the ...
... , FRIDAY, June 24 (HealthDay News) -- Drinking even ... concentrations enough to increase the chances of being seriously injured ... get behind the wheel, a new study suggests. Researchers ... a blood-alcohol concentration of just 0.01 percent -- much lower ...
... June 24, 2011 A new anti-inflammatory drug used by ... a year-long study involving researchers from UT Southwestern Medical Center. ... Journal of Medicine , mark the first time a drug ... type 2 diabetes and chronic kidney disease. Previous studies have ...
... Researchers from Boston University,s Slone Epidemiology Center have found ... (MHC) that confer a higher risk of systemic lupus ... currently appears on-line in Human Genetics , is ... association between genetic variants in the MHC region and ...
... , THURSDAY, June 23 (HealthDay News) -- After suffering a ... and fears about the future are less depressed and live ... In fact, 48 percent of the people who participated in ... were not depressed a year later, compared to 37.7 of ...
... (HealthDay News) -- New research suggests that the adverse effects ... latest findings, from a University of Rhode Island study that ... revealed that preemies grow up to be less healthy, struggle ... compared to those born full-term. One reason for this, ...
Cached Medicine News:Health News:Even One Glass of Beer, Wine Boosts Car Crash Risk: Study 2Health News:Drug shows improved kidney function for type 2 diabetics, UT Southwestern researchers report 2Health News:New genetic risk factors of lupus found in study of African-American women 2Health News:Early Talk Therapy May Help Stroke Patients Bounce Back 2Health News:Early Talk Therapy May Help Stroke Patients Bounce Back 3Health News:Effects of Premature Birth May Stretch Into Adulthood: Study 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: